Printer Friendly

Now Available: Colon Carcinoma - Pipeline Review, H2 2013.

[USPRwire, Wed Oct 30 2013] Global Markets Direct's, 'Colon Carcinoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Colon Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Carcinoma. Colon Carcinoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Full Report Details at


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


* A snapshot of the global therapeutic scenario for Colon Carcinoma.

* A review of the Colon Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

* Coverage of products based on various stages of development ranging from discovery till registration stages.

* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

* Coverage of the Colon Carcinoma pipeline on the basis of route of administration and molecule type.

* Key discontinued pipeline projects.

* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Colon Carcinoma.

* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

* Devise corrective measures for pipeline projects by understanding Colon Carcinoma pipeline depth and focus of Indication therapeutics.

* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: AIMM Therapeutics B.V., PepTx, Inc.

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Colon Cancer - Pipeline Review, H2 2013

- Renal Cell Carcinoma - Pipeline Review, H2 2013

- Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2013

- Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2013

- Colon Carcinoma - Pipeline Review, H1 2013

Copyright 2013 USPRwire

Provided by an company
COPYRIGHT 2013 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Date:Oct 30, 2013
Previous Article:Market Report, "Russia Pharmaceuticals & Healthcare Report Q4 2013", published.
Next Article:Australia Consumer Electronics Report Q4 2013 - New Market Research Report.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters